secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2026-05-13T20:41:28+00:00
Accession:  0001437749-26-016760
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva Q1 net loss $3.2M; stock moving from Nasdaq to OTCQB effective May 14
----------------------------------------------------------------------------

- Net loss $3.2M ($0.46/share) vs $6.4M ($2.61) in Q1 2025; cash $22.2M up from $14.4M.
- Completed public equity offering raising $10M gross in March 2026.
- Filed provisional patent for new brilaroxazine form to extend exclusivity through 2046; FDA feedback expected mid-2026.
- RECOVER-2 Phase 3 schizophrenia trial enrollment planned for Q3 2026.
- Common stock to stop trading on Nasdaq and move to OTCQB on May 14, 2026, under symbol RVPH.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774926016760/0001437749-26-016760-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774926016760/rvph20260513_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-016760

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer